한빛사논문
James L. Shepherdson,1,46 Katie Hutchison,2,46 Dilan Wellalage Don,3,46 George McGillivray,4,5 Tae-Ik Choi,3 Carolyn A. Allan,6 David J. Amor,5,7 Siddharth Banka,8,9 Donald G. Basel,10 Laura D. Buch,11 Deanna Alexis Carere,12 Rene´e Carroll,13 Jill Clayton-Smith,14 Ali Crawford,15 Morten Dunø,16 Laurence Faivre,17,18 Christopher P. Gilfillan,19,20 Nina B. Gold,21,22 Karen W. Gripp,23 Emma Hobson,24 Alexander M. Holtz,25 A. Micheil Innes,26 Bertrand Isidor,27,28 Adam Jackson,8,9 Panagiotis Katsonis,29 Leila Amel Riazat Kesh,24 Genomics England Research Consortium, Se´bastien Ku¨ry,27,28 Franc¸ois Lecoquierre,30 Paul Lockhart,5,7 Julien Maraval,17,18 Naomichi Matsumoto,31 Julie McCarrier,10 Josephine McCarthy,20 Noriko Miyake,31,32 Lip Hen Moey,33 Andrea H. Ne´meth,34,35 Elsebet Østergaard,16,36 Rushina Patel,37 Kate Pope,5 Jennifer E. Posey,29 Rhonda E. Schnur,12 Marie Shaw,13 Elliot Stolerman,11 Julie P. Taylor,15 Erin Wadman,23 Emma Wakeling,38 Susan M. White,4,5,7 Lawrence C. Wong,39 James R. Lupski,29,40,41,42 Olivier Lichtarge,29 Mark A. Corbett,13 Jozef Gecz,13,43 Charles M. Nicolet,2 Peggy J. Farnham,2,45 Cheol-Hee Kim,3,45,* and Marwan Shinawi44,45,*
1Medical Scientist Training Program, Washington University School of Medicine, St. Louis, MO, USA;
2Department of Biochemistry and Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA;
3Department of Biology, Chungnam National University, Daejeon 34134, Korea;
4Victorian Clinical Genetics Services, Parkville, VIC 3052, Australia;
5Murdoch Children’s Research Institute, Parkville, VIC 3052, Australia;
6Hudson Institute of Medical Research, Monash University, and Department of Endocrinology, Monash Health, Melbourne, Australia;
7Department of Paediatrics, The University of Melbourne, Parkville 3052, VIC, Australia;
8Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK;
9Manchester Centre for Genomic Medicine, St Mary’s Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK;
10Division of Genetics, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA;
11Greenwood Genetic Center, Greenwood, SC, USA;
12GeneDx, Gaithersburg, MD 20877, USA;
13Adelaide Medical School and Robinson Research Institute, The University of Adelaide, Adelaide, SA, Australia;
14Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK;
15Medical Genomics Research, Illumina Inc, San Diego, CA, USA;
16Department of Clinical Genetics, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark;
17Centre de Re´fe´rence Anomalies du De´veloppement et Syndromes Malformatifs, FHU TRANSLAD, Hoˆpital d’Enfants, Dijon, France;
18INSERM UMR1231, Equipe GAD, Universite´ de Bourgogne-Franche Comte´, 21000 Dijon, France;
19Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia;
20Department of Endocrinology, Eastern Health, Box Hill Hospital, Melbourne, VIC, Australia;
21Harvard Medical School, Boston, MA, USA;
22Division of Medical Genetics and Metabolism, Massachusetts General Hospital, Boston, MA, USA;
23Division of Medical Genetics, Nemours Children’s Hospital, Wilmington, DE, USA;
24Yorkshire Regional Genetics Service, Leeds Teaching Hospitals NHS Trust, Department of Clinical Genetics, Chapel Allerton Hospital, Leeds, UK;
25Division of Genetics and Genomics, Boston Children’s Hospital, Boston, MA, USA;
26Departments of Medical Genetics and Pediatrics and Alberta Children’s Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada;
27Nantes Universite´, CHU Nantes, Service de Ge´ne´tique Me´dicale, 44000 Nantes, France;
28Nantes Universite´, CHU Nantes, CNRS, INSERM, l’institut du Thorax, 44000 Nantes, France;
29Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA;
30Univ Rouen Normandie, Inserm U1245 and CHU Rouen, Department of Genetics and Reference Center for Developmental Disorders, 76000 Rouen, France;
31Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan;
32Department of Human Genetics, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, Japan;
33Department of Genetics, Penang General Hospital, George Town, Penang, Malaysia;
34Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK;
35Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK;
36Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark;
37Medical Genetics, Kaiser Permanente Oakland Medical Center, Oakland, CA, USA;
38North East Thames Regional Genetic Service, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK;
39Medical Genetics, Kaiser Permanente Downey Medical Center, Downey, CA, USA;
40Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA;
41Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA;
42Texas Children’s Hospital, Houston, TX, USA;
43South Australian Health and Medical Research Institute, Adelaide, SA, Australia;
44Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
45Senior authors
46These authors contributed equally
*Correspondence: C.-H.K., M.S.
Abstract
Pathogenic variants in multiple genes on the X chromosome have been implicated in syndromic and non-syndromic intellectual disability disorders. ZFX on Xp22.11 encodes a transcription factor that has been linked to diverse processes including oncogenesis and development, but germline variants have not been characterized in association with disease. Here, we present clinical and molecular characterization of 18 individuals with germline ZFX variants. Exome or genome sequencing revealed 11 variants in 18 subjects (14 males and 4 females) from 16 unrelated families. Four missense variants were identified in 11 subjects, with seven truncation variants in the remaining individuals. Clinical findings included developmental delay/intellectual disability, behavioral abnormalities, hypotonia, and congenital anomalies. Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities. Hyperparathyroidism was found in four families with missense variants, and enrichment of different tumor types was observed. In molecular studies, DNA-binding domain variants elicited differential expression of a small set of target genes relative to wild-type ZFX in cultured cells, suggesting a gain or loss of transcriptional activity. Additionally, a zebrafish model of ZFX loss displayed an altered behavioral phenotype, providing additional evidence for the functional significance of ZFX. Our clinical and experimental data support that variants in ZFX are associated with an X-linked intellectual disability syndrome characterized by a recurrent facial gestalt, neurocognitive and behavioral abnormalities, and an increased risk for congenital anomalies and hyperparathyroidism.
논문정보
관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기